AstraZeneca Loses Bid to Dismiss Seroquel Pay-for-Delay Lawsuits

AstraZeneca LP lost a consolidated bid to dismiss antitrust claims arising from an allegedly unlawful agreement with Handa Pharmaceuticals LLC, after a federal court in Delaware said the plaintiffs adequately alleged an impermissible agreement to limit competition in the market for extended release quetiapine fumarate, or Seroquel XR.

The U.S. District Court for the District of Delaware however, dismissed claims arising from a similar arrangement between AstraZeneca’s and Accord Pharmaceuticals Inc.

The direct purchasers, one of three groups of plaintiffs in the consolidated lawsuits, didn’t allege that AstraZeneca’s deal with Accord was entered into for an anti-competitive purpose, according to ...